Cargando…

Therapeutic ROS and Immunity in Cancer—The TRIC-21 Meeting

The first Therapeutic ROS and Immunity in Cancer (TRIC) meeting was organized by the excellence research center ZIK plasmatis (with its previous Frontiers in Redox Biochemistry and Medicine (FiRBaM) and Young Professionals’ Workshop in Plasma Medicine (YPWPM) workshop series in Northern Germany) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Bekeschus, Sander, Emmert, Steffen, Clemen, Ramona, Boeckmann, Lars
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471836/
https://www.ncbi.nlm.nih.gov/pubmed/34572777
http://dx.doi.org/10.3390/cancers13184549
_version_ 1784574570285498368
author Bekeschus, Sander
Emmert, Steffen
Clemen, Ramona
Boeckmann, Lars
author_facet Bekeschus, Sander
Emmert, Steffen
Clemen, Ramona
Boeckmann, Lars
author_sort Bekeschus, Sander
collection PubMed
description The first Therapeutic ROS and Immunity in Cancer (TRIC) meeting was organized by the excellence research center ZIK plasmatis (with its previous Frontiers in Redox Biochemistry and Medicine (FiRBaM) and Young Professionals’ Workshop in Plasma Medicine (YPWPM) workshop series in Northern Germany) and the excellence research program ONKOTHER-H (Rostock/Greifswald, Germany). The meeting showcased cutting-edge research and liberated discussions on the application of therapeutic ROS and immunology in cancer treatment, primarily focusing on gas plasma technology. The 2-day hybrid meeting took place in Greifswald and online from 15–16 July 2021, facilitating a wide range of participants totaling 66 scientists from 12 countries and 5 continents. The meeting aimed at bringing together researchers from a variety of disciplines, including chemists, biochemists, biologists, engineers, immunologists, physicists, and physicians for interdisciplinary discussions on using therapeutic ROS and medical gas plasma technology in cancer therapy with the four main sessions: “Plasma, Cancer, Immunity”, “Plasma combination therapies”, “Plasma risk assessment and patients studies”, and “Plasma mechanisms and treated liquids in cancer”. This conference report outlines the abstracts of attending scientists submitted to this meeting.
format Online
Article
Text
id pubmed-8471836
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84718362021-09-28 Therapeutic ROS and Immunity in Cancer—The TRIC-21 Meeting Bekeschus, Sander Emmert, Steffen Clemen, Ramona Boeckmann, Lars Cancers (Basel) Conference Report The first Therapeutic ROS and Immunity in Cancer (TRIC) meeting was organized by the excellence research center ZIK plasmatis (with its previous Frontiers in Redox Biochemistry and Medicine (FiRBaM) and Young Professionals’ Workshop in Plasma Medicine (YPWPM) workshop series in Northern Germany) and the excellence research program ONKOTHER-H (Rostock/Greifswald, Germany). The meeting showcased cutting-edge research and liberated discussions on the application of therapeutic ROS and immunology in cancer treatment, primarily focusing on gas plasma technology. The 2-day hybrid meeting took place in Greifswald and online from 15–16 July 2021, facilitating a wide range of participants totaling 66 scientists from 12 countries and 5 continents. The meeting aimed at bringing together researchers from a variety of disciplines, including chemists, biochemists, biologists, engineers, immunologists, physicists, and physicians for interdisciplinary discussions on using therapeutic ROS and medical gas plasma technology in cancer therapy with the four main sessions: “Plasma, Cancer, Immunity”, “Plasma combination therapies”, “Plasma risk assessment and patients studies”, and “Plasma mechanisms and treated liquids in cancer”. This conference report outlines the abstracts of attending scientists submitted to this meeting. MDPI 2021-09-10 /pmc/articles/PMC8471836/ /pubmed/34572777 http://dx.doi.org/10.3390/cancers13184549 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Conference Report
Bekeschus, Sander
Emmert, Steffen
Clemen, Ramona
Boeckmann, Lars
Therapeutic ROS and Immunity in Cancer—The TRIC-21 Meeting
title Therapeutic ROS and Immunity in Cancer—The TRIC-21 Meeting
title_full Therapeutic ROS and Immunity in Cancer—The TRIC-21 Meeting
title_fullStr Therapeutic ROS and Immunity in Cancer—The TRIC-21 Meeting
title_full_unstemmed Therapeutic ROS and Immunity in Cancer—The TRIC-21 Meeting
title_short Therapeutic ROS and Immunity in Cancer—The TRIC-21 Meeting
title_sort therapeutic ros and immunity in cancer—the tric-21 meeting
topic Conference Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471836/
https://www.ncbi.nlm.nih.gov/pubmed/34572777
http://dx.doi.org/10.3390/cancers13184549
work_keys_str_mv AT bekeschussander therapeuticrosandimmunityincancerthetric21meeting
AT emmertsteffen therapeuticrosandimmunityincancerthetric21meeting
AT clemenramona therapeuticrosandimmunityincancerthetric21meeting
AT boeckmannlars therapeuticrosandimmunityincancerthetric21meeting